Open terminalDashboard

DevelopingDeveloping · Updated 4:58 PM ET · 1 update

Merck Ends Nemtabrutinib Trials for Blood Cancer Drug

Merck discontinued development of nemtabrutinib, an experimental blood cancer drug, the company said Tuesday.

More on this company

  1. Merck said in a Tuesday release that it is discontinuing the clinical development program for nemtabrutinib (MK-1026), an experimental oral drug being studied for blood cancers.

What happened

Merck announced on Tuesday that it is stopping the clinical trials evaluating nemtabrutinib, an investigational, non-covalent Bruton's tyrosine kinase (BTK) inhibitor taken orally, which had been studied in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, among other blood cancers. Shortly after, Reuters reported that Merck halted the trials following a risk assessment of the drug.

How the stock has moved

Merck shares closed at $143.37 on Tuesday. No trading could be observed after that close, so it is not yet clear how the stock has responded since the news broke.

Merck & Co. (MRK) since the news
MeasureValue
Last close (Tuesday, November 17, 2026)$143.37
Market value at the close on Tuesday, November 17, 2026$353.44 billion

Source: Stock quote; the close before the first report from our saved closes · as of November 17, 2026 at 4:58 PM ET · Shows what the stock did after the news was first reported, not why.

Its suppliers and customers

Company filings list Verona Pharma, Sidera Therapeutics and Doctor Fultz Pharma as suppliers to Merck. None of the three, which are not publicly listed, showed any trading activity since their last recorded close.

Suppliers and customers of Merck, and how they are trading
CompanyRoleStockSince last close
Verona PharmaSupplierNot listed—
Sidera TherapeuticsSupplierNot listed—
Doctor Fultz PharmaSupplierNot listed—

Source: Relationships named in company filings (Earnings call transcript); stock quotes · as of November 17, 2026 at 4:58 PM ET · A supplier or customer moving the same day is not evidence that one move caused the other.

Sources

  • — Reuters

How this was made

Written from WiseView data and the sources credited above, and checked before it went up. It is updated as new reports come in, and every update is checked before it goes up. How this report is made

For information only, not investment advice.

More from the desk

Follow MRK in the terminal.

Every panel, HootAI, the squawk and the pre-market board, on one membership.

Annual

$83/mo

Billed annually, $997 once a year.

Monthly

$127/mo

Billed monthly. Cancel any time.

14-day free trial · no card needed · nothing to cancel. Buying for a team? Seats on one invoice.